OPNT Nasdaq

Opiant Pharmaceuticals, Inc.

OPNT | $20.65 -0.58% 0.48% 0

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (74.95% volume)
Earnings Calendar: 2023-03-14
Market Cap: $ 106,639,718
http://www.opiant.com
Sec Filling | Patents | 21 employees

Opiant Pharmaceuticals, Inc. engages in the development of pharmaceutical solutions for common addictions and related disorders. It focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. Opiant Pharmaceuticals was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

opioid treatment injection

add to watch list Paper trade email alert is off

Press-releases

Brand Institute Partners on Brand Name Development for FDA-Approved Nasal Spray to Reverse Fentanyl and Other Opioid Overdoses
Published: 2023-05-30 (Crawled : 17:00) - biospace.com/
OPNT | $20.65 -0.58% 0.48% 0

Health Technology

| Email alert Add to watchlist
institute opioid spray

Indivior Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl
Published: 2023-05-22 (Crawled : 00:00) - prnewswire.com
OPNT | $20.65 -0.58% 0.48% 0

Health Technology

| Email alert Add to watchlist
opvee drug opioid natural approval food

Indivior Announces Q1 2023 Financial Results
Published: 2023-04-27 (Crawled : 11:00) - prnewswire.com
OPNT | $20.65 -0.58% 0.48% 0

Health Technology

| Email alert Add to watchlist
financial results

Indivior Completes Acquisition of Opiant Pharmaceuticals, Inc.
Published: 2023-03-02 (Crawled : 22:00) - biospace.com/
OPNT | $20.65 -0.58% 0.48% 0

Health Technology

| Email alert Add to watchlist
acquisition

Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC
Published: 2023-02-07 (Crawled : 23:00) - biospace.com/
OPNT | $20.65 -0.58% 0.48% 0

Health Technology

| -0.14% | O: -0.38% H: 0.0% C: 0.0%
acquisition pharmaceuticals approval

Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose
Published: 2023-01-19 (Crawled : 00:00) - biospace.com/
OPNT | $20.65 -0.58% 0.48% 0

Health Technology

| 1.91% | O: 0.32% H: 0.0% C: 0.0%
opnt003 fda pharmaceuticals opioid review

Indivior Capital Markets Day Highlights Strategy for Shareholder Value Creation and Attractive Medium-Term Profitable Growth Outlook
Published: 2022-12-07 (Crawled : 08:00) - prnewswire.com
OPNT | $20.65 -0.58% 0.48% 0

Health Technology

| 2.75% | O: -0.32% H: 0.79% C: 0.25%
day profitable growth

EQUITY ALERT: The M&A Class Action Firm Announces the Investigation of Opiant Pharmaceuticals, Inc. - OPNT
Published: 2022-11-15 (Crawled : 04:00) - prnewswire.com
OPNT | $20.65 -0.58% 0.48% 0

Health Technology

| 2.57% | O: 0.1% H: 0.1% C: -0.44%

Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results
Published: 2022-11-14 (Crawled : 08:00) - globenewswire.com
OPNT | $20.65 -0.58% 0.48% 0

Health Technology